Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous amlitelimab in moderate-to-severe asthma (dose-ranging)
2022-000065-41Phase 2Active
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in asthma (4 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of severe exacerbation events over 48 weeks. Started Jun 2022; status: active.
02
Drugs
amlitelimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-000065-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000065-41.